Intraductal Papillary Mucinous Neoplasms of the Pancreas (IPMNs): New Insights on Clinical Outcomes and Malignant Progression
Intraductal papillary mucinous neoplasms (IPMNs) are cystic tumors of the pancreas that can progress into invasive carcinomas. Main duct IPMN is usually treated with surgery while branch duct IPMN is surgically resected if it is high risk based on certain features of the tumor (mostly radiographic) that do have some limitations. Predicting the risk of malignant progression has been lately the main focus of research especially that comprehending the molecular pathogenesis of the disease has emerged as a valuable means to better understand the disease and thus guide disease management. We will present two abstracts from the ASCO Annual Meeting. The first compares the clinical outcomes of pancreatic ductal carcinoma and IPMN associated cancer, and the second looks at the pathogenesis of the disease at the cellular and molecular levels to predict high risk disease.
Image: Stained glass windows by Tommaso Juglaris at Goddard Chapel at Tufts University. Medford, MA, USA
Correa-Gallego C, Do R, Lafemina J, Gonen M, D'Angelica MI, DeMatteo RP, Fong Y, et al. Predicting dysplasia and invasive carcinoma in intraductal papillary mucinous neoplasms of the pancreas: development of a preoperative nomogram. Ann Surg Oncol. 2013; 20: 4348-55. [PMID:24046103]
Bassi C, Sarr MG, Lillemoe KD, Reber HA. Natural history of intraductal papillary mucinous neoplasms (IPMN): current evidence and implications for management. J Gastrointest Surg. 2008; 12: 645-50. [PMID:18097728]
Krishna K, Bloomston M, Muscarella P, Krishna S, Wei L, Conwell D, Bekaii-Saab TS. Comparative outcomes of patients with intraductal papillary mucinous neoplasm associated cancer (IPMN-Ca) to those with pancreatic ductal carcinoma (PDAC) following resection. J Clin Oncol. 2014; 32. Abstract e15227.
Sadot E, Basturk O, Klimstra DS, Gonen M, et al. Infiltrating neutrophils and malignant progression in intraductal papillary mucinous neoplasms (IPMN): An opportunity for identification of high-risk disease. J Clin Oncol. 2014; 32: 5s. Abstract 4137.
Iannicelli E, Carbonetti F, Di Pietropaolo M, Federici GF, Capurso G, David V. Magnetic resonance cholangiopancreatography with secretin stimulation in the diagnosis of intraductal papillary mucinous neoplasm: a paradigmatic case report. Case Rep Radiol. 2014; 2014: 820359. [PMID:24716074]
Chen F, Liang JY, Zhao QY, Wang LY, Li J, Deng Z, Jiang TA. Differentiation of branch duct intraductal papillary mucinous neoplasms from serous cystadenomas of the pancreas using contrast-enhanced sonography. J Ultrasound Med. 2014; 33: 449-55. [PMID:24567456]
Goh BK, Tan DM, Ho MM, Lim TK, Chung AY, Ooi LL. Utility of the Sendai Consensus Guidelines for Branch-Duct Intraductal Papillary Mucinous Neoplasms: A Systematic Review. J Gastrointest Surg. 2014; 18: 1350-7 [PMID:24668367]
Shi C, Hruban RH. Intraductal papillary mucinous neoplasm. Hum Pathol. 2012; 43: 1-16. [PMID:21777948]
Grutzmann R, Niedergethmann M, Pilarsky C, Kloppel G, Saeger HD. Intraductal papillary mucinous tumors of the pancreas: biology, diagnosis, and treatment. Oncologist. 2010; 15: 1294-309. [PMID:21147870]
Schönleben F, Qiu W, Bruckman KC, Ciau NT, Li X, Lauerman MH, Frucht H, et al. BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas. Cancer Lett. 2007; 249: 242-8. [PMID:17097223]
Schonleben F, Qiu W, Remotti HE, Hohenberger W, Su GH. PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas. Langenbecks Arch Surg. 2008; 393: 289-96. [PMID:18343945]
Winner M, Epelboym I, Remotti H, Lee JL, Schrope BA, Chabot JA, Allendorf JD. Predictors of recurrence in intraductal papillary mucinous neoplasm: experience with 183 pancreatic resections. J Gastrointest Surg. 2013; 17: 1618-26. [PMID:23813047]
Wasif N, Bentrem DJ, Farrell JJ, Ko CY, Hines OJ, Reber HA, Tomlinson JS. Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes. Cancer. 2010; 116: 3369-77. [PMID:20564064]
Woo SM, Ryu JK, Lee SH, Yoo JW, Park JK, Kim YT, Yoon YB. Survival and prognosis of invasive intraductal papillary mucinous neoplasms of the pancreas: comparison with pancreatic ductal adenocarcinoma. Pancreas. 2008; 36: 50-5. [PMID:18192881]
Copyright (c) 2014 Jack Khouri, Muhammad Wasif Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.